Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 35.20

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (193)	4/21/2004 11:50:41 AM
From: keokalani'nui	of 566

My notes on the UL program are 2 years old. (!) They had it (one or more cpds) in colon and breast models. In colon it was 'as good as 5fu'. In lung cancer it was given with +- taxol and was potent, but not as potent as t--no notes on synergy. Found it selective for tumor type and selective vs normal tissue. As of 1/02 they were doing tox, '4-6 mos behind asthma'. Clearly there was more work needed, but then the company made some seriously hubris-like mistakes in not doing a financing and may simply have had to husband $$$. Shortly after 2002 HnQ, the co in-lincensed IP on ROC1 from academia (ubiquitin ligase target possibly effecting oncology and inflam). Sorry, though I held onto most of my Rigel throughout the slide rigl ended up in my mental dog house where it whimpered and played dead, and I haven't keep up with developments. The company has not exactly gone out of its way to make friends with individual investors anyway. They used to crow about being at the forefront of UL development.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next